Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority

Bhooma Venkatraman

doi:10.4103/2395-3977.192931

Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority

Bhooma Venkatraman

Research output: Contribution to journal › Article › peer-review

86 Downloads (Pure)

Abstract

Triple‑negative breast cancer (TNBC) remains a significant clinical and scientific challenge. The classification of TNBC is based on the lack of expression of the human epidermal growth factor 2, the estrogen receptor, and the progesterone receptor. TNBC accounts for more than 20% of all breast cancers (BCs), has a poorer prognosis compared to other BC subtypes, and has no targeted therapeutics. Primarily, this review focuses on the heterogeneity of BC and the importance of molecular subtyping for the accurate classification of TNBC. Further, it seeks to identify the molecular "omic" gaps in subtyping TNBC and the role of membrane protein biomarkers that could potentially advance clinical and translational research in BC.

Original language	English
Pages (from-to)	137-146
Number of pages	10
Journal	Cancer translational medicine
Volume	2
Issue number	5
DOIs	https://doi.org/10.4103/2395-3977.192931
Publication status	Published - 2016

Bibliographical note

Copyright Cancer Translational Medicine 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

biomarkers and membrane proteins
breast cancer
metastasis
triple negative

Access to Document

10.4103/2395-3977.192931

Mq-61253-Publisher version (open access)Final published version, 1.39 MBLicence: Unspecified

Cite this

@article{a46353a7e57e4bf4a8081f3bd2d2766a,

title = "Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority",

abstract = "Triple‑negative breast cancer (TNBC) remains a significant clinical and scientific challenge. The classification of TNBC is based on the lack of expression of the human epidermal growth factor 2, the estrogen receptor, and the progesterone receptor. TNBC accounts for more than 20\% of all breast cancers (BCs), has a poorer prognosis compared to other BC subtypes, and has no targeted therapeutics. Primarily, this review focuses on the heterogeneity of BC and the importance of molecular subtyping for the accurate classification of TNBC. Further, it seeks to identify the molecular {"}omic{"} gaps in subtyping TNBC and the role of membrane protein biomarkers that could potentially advance clinical and translational research in BC.",

keywords = "biomarkers and membrane proteins, breast cancer, metastasis, triple negative",

author = "Bhooma Venkatraman",

note = "Copyright Cancer Translational Medicine 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2016",

doi = "10.4103/2395-3977.192931",

language = "English",

volume = "2",

pages = "137--146",

journal = "Cancer translational medicine",

issn = "2395-3977",

publisher = "Medknow Publications",

number = "5",

}

TY - JOUR

T1 - Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority

AU - Venkatraman, Bhooma

N1 - Copyright Cancer Translational Medicine 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2016

Y1 - 2016

N2 - Triple‑negative breast cancer (TNBC) remains a significant clinical and scientific challenge. The classification of TNBC is based on the lack of expression of the human epidermal growth factor 2, the estrogen receptor, and the progesterone receptor. TNBC accounts for more than 20% of all breast cancers (BCs), has a poorer prognosis compared to other BC subtypes, and has no targeted therapeutics. Primarily, this review focuses on the heterogeneity of BC and the importance of molecular subtyping for the accurate classification of TNBC. Further, it seeks to identify the molecular "omic" gaps in subtyping TNBC and the role of membrane protein biomarkers that could potentially advance clinical and translational research in BC.

AB - Triple‑negative breast cancer (TNBC) remains a significant clinical and scientific challenge. The classification of TNBC is based on the lack of expression of the human epidermal growth factor 2, the estrogen receptor, and the progesterone receptor. TNBC accounts for more than 20% of all breast cancers (BCs), has a poorer prognosis compared to other BC subtypes, and has no targeted therapeutics. Primarily, this review focuses on the heterogeneity of BC and the importance of molecular subtyping for the accurate classification of TNBC. Further, it seeks to identify the molecular "omic" gaps in subtyping TNBC and the role of membrane protein biomarkers that could potentially advance clinical and translational research in BC.

KW - biomarkers and membrane proteins

KW - breast cancer

KW - metastasis

KW - triple negative

U2 - 10.4103/2395-3977.192931

DO - 10.4103/2395-3977.192931

M3 - Article

SN - 2395-3977

VL - 2

SP - 137

EP - 146

JO - Cancer translational medicine

JF - Cancer translational medicine

IS - 5

ER -

Identifying gaps and relative opportunities for discovering membrane proteomic biomarkers of triple-negative breast cancer as a translational priority

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this